N. A. Giese

CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, Demonstrates Clinical Activity and Pharmacodynamic Effects In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Richard R. Furman, John C. Byrd, Jennifer R. Brown et al. · Blood · 2010 · 124 citations

Medicine, Oncology, Pharmacology +12

Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Brad S. Kahl, John C. Byrd, Ian W. Flinn et al. · Blood · 2010 · 109 citations

Medicine, Oncology, Pharmacology +12

Interim results from a phase I study of CAL-101, a selective oral inhibitor of phosphatidylinositol 3-kinase p110d isoform, in patients with relapsed or refractory hematologic malignancies.

Richard R. Furman, John C. Byrd, Ian W. Flinn et al. · Journal of Clinical Oncology · 2010 · 43 citations

Medicine, Hematology, Pharmacology +12

Preliminary evidence of clinical activity in a phase I study of CAL-101, a selective inhibitor of the p1108 isoform of phosphatidylinositol 3-kinase (P13K), in patients with select hematologic malignancies

Ian W. Flinn, John C. Byrd, Richard R. Furman et al. · Journal of Clinical Oncology · 2009 · 18 citations

Medicine, Oncology, Pharmacology +15